Back to search results

Curcumin After Prostatectomy for Prostate Cancer

This study is looking at whether curcumin, a natural compound, can help prevent prostate cancer from coming back after surgery. You would take either curcumin or a placebo (an inactive pill) by mouth twice a day for 6 months. The study is for men aged 30 to 80 who have had surgery for prostate cancer that hasn't spread. Researchers will measure your PSA (prostate specific antigen) levels after 3 years to see if curcumin helps reduce the chance of recurrence. The current status of this study is unclear.

Study design
This is an interventional study planning to enroll 650 men. It compares curcumin to a placebo.
What's involved
You would take curcumin or a placebo by mouth twice a day for 6 months.
Compensation
Not stated in the trial record.
Follow-up
Your PSA levels will be measured at 3 years after starting the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT02064673

Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy

Recruiting
PHASE3Ages 30–80InterventionalTreatment
yair lotan
~650 participants
Updated 2026-03-30 on ClinicalTrials.gov
What's tested:Curcuminplacebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Serum prostate specific antigen
Measured over 3 years

Conditions

Prostate Cancer

Explore related trials

Prostate Carcinoma

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Yair Lotan, MD · PRINCIPAL_INVESTIGATOR · University of Texas Southwestern Medical Center

Who to contact

Corey Nixon
[email protected]
214-645-8787
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Status post radical prostatectomy for histologically confirmed adenocarcinoma of the prostate
pathologically confirmed T1-T3 disease
no sign of lymph node or metastatic disease
pT1-pT3pNxMx patients in whom standard NCCN or AUA guidelines would suggest are at low risk for pelvic lymph node or metastatic disease and who would not require confirmatory imaging for metastatic disease. This includes patients with Gleason 6 or 7(T2 disease) and PSA less than 20.
Eastern Cooperative Oncology Group(ECOG) status 0-2
adequate renal and liver function as well as bone marrow reserve (measured serum creatinine \<2mg/dl, bilirubin ≤ 1.5 mg/dl, ANC ≥ 1.5 x 10 (3) uL, platelets ≥ 50 x K/uLL, and hemoglobin ≥ 10 g/dL)
30-80 y/o at time of diagnosis with a life expectancy of \>= 3 yrs
focally positive surgical margins are permitted
no plan to receive adjuvant hormone or radiation therapy
PSA at the time of enrollment must be undetectable
life expectancy of 3 years

Exclusion

must not have exceeded 3 months from time of surgery to enrollment into study
T3b or T4 or node positive disease
macroscopic residual disease after surgery
hormone therapy before surgery
history of gallbladder problems or gallstones, or biliary obstruction, unless patient had cholecystectomy
radiation therapy as primary treatment after surgery
INR value greater than 1.5
AST/ALT are equal or greater than 2 times the upper limit of normal
antiplatelet or anticoagulant agents- patients taking 81mg of Aspirin will be allowed with close observation
history of gastric or duodenal ulcers or untreated hyperacidity syndromes
patients who are currently taking curcumin and are unwilling to stop or plan to take curcumin during the study

What this trial measures

  • Serum prostate specific antigen3 years

    Recurrence free survival defined as a total serum prostate specific antigen of \<0.2ng/ml.